Navigation Links
Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial
Date:5/21/2009

1,000 deaths in the EU each year.(7) Coronary artery disease occurs when the arteries become narrowed or clogged by cholesterol and fat deposits and cannot supply enough blood to the heart. In some cases, a blood clot may partially or totally block the blood supply to the heart, resulting in ACS.(8) Many ACS patients are managed with PCI, which usually includes a stent placement.

About Prasugrel

Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke.

About Daiichi Sankyo

A global pharmaceutical innovator, Daiichi Sankyo Company, Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Areas of central focus for Daiichi Sankyo research and development are thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to the company are hypertension, hyperlipidemia or atherosclerosis and bacterial infections. For more information, visit www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Par
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Agendia to Present Multiple Predictive and Prognostic Studies on Breast and Colorectal Cancers at ASCO Annual Meeting
2. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
3. Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
5. Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis
6. Intrinsic Bioprobes, Inc. Enters into a $1.27M Contract with the National Cancer Institute to Develop Multiplex Mass Spectrometric Immunoassays for Detection of Low Abundance Cancer-Related Proteins
7. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
8. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
9. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
10. Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology
11. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... SoundConnect’s 2015 next ... edge communication technology, provide continued education and inform ... series demonstrates online communication features and benefits; empowering ... most innovative and powerful tools. , According to ...
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ...
(Date:12/24/2014)... 23, 2014 Nashville Fertility Center announced that ... the American Society for Reproductive Medicine (ASRM), a leading professional ... In his new role as treasurer, Dr. Hill also ... a voice in furthering the mission of ASRM. , ...
Breaking Biology Technology:Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... (Amex: PTN ) announced today financial results for ... net loss of $247,000, or $0.00,per basic and diluted ... a net loss of $8.4 million, or ($0.12) per ... Total revenues for the quarter ended,September 30, 2007 were ...
... 9 at 8:00 a.m. PST -, SAN ... HALO ), a biopharmaceutical company developing and commercializing,products ... for the three and nine months ended September ... the complexities of the,extracellular matrix provide a number ...
... 8 Kosan Biosciences,Incorporated (Nasdaq: KOSN ) today reported ... 2007. Net loss for the quarter and nine months ... $0.26 per share and $0.46 per share,compared to a net ... per share, in the same periods last year. Revenues ...
Cached Biology Technology:Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 2Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 3Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 4Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 5Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007 6Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 2Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 3Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 4Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 5Halozyme Therapeutics Reports 2007 Third Quarter Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 2Kosan Announces Third Quarter 2007 Financial Results 3Kosan Announces Third Quarter 2007 Financial Results 4Kosan Announces Third Quarter 2007 Financial Results 5Kosan Announces Third Quarter 2007 Financial Results 6Kosan Announces Third Quarter 2007 Financial Results 7
(Date:12/11/2014)... Research and Markets , ... announced the addition of the "Biometrics Market in ... One major trend emerging in this market is ... utilize more than one characteristic of an individual for ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: you desperately ... your password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital infrastructure security ... end to the frustration that comes with usernames, passwords and PINs ...
(Date:12/10/2014)... SAN DIEGO , Dec. 9, 2014 CIE San ... that provides the connective tissue that enhances care coordination among ... share client-level information; earned a second $1 million grant from ... aging in community and; will be recognized as a "Live ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... biological weapons are created equal. They are separated into ... the scariest: They are easy to spread, kill effectively ... system. One of these worrisome organisms is anthrax, which ... But work in Vince Fischetti's laboratory at Rockefeller University ...
... National Institute of Allergy and Infectious Diseases (NIAID), ... today announced that enrollment into a large international ... drug treatment guided by levels of CD4+ cells ... patients receiving episodic therapy had twice the risk ...
... Scientists at Karolinska Institutet in Sweden have helped to ... vaccination agent against growing cancer tumours. Although the results ... to new methods of treating metastases. , The results ... scientific journal Nature Medicine, and represent the collaborative efforts ...
Cached Biology News:Newly discovered protein kills anthrax bacteria by exploding their cell walls 2International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 2International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 3International HIV/AIDS trial finds continuous antiretroviral therapy superior to episodic therapy 4
E2F2 protein...
Rabbit Anti-melatonin (different linkage) Polyclonal Antibody...
... Goat polyclonal to Cholesterol Oxidase ... / Specificity Cross-reacts with bacteria. Not ... Information Cholesterol oxidases exist as both ... are implicated in bacterial pathogenesis. In addition, ...
Phospho-PERK (Thr980) Antibody...
Biology Products: